rs794727701
Variant summary
Our verdict is Likely pathogenic. Variant got 7 ACMG points: 7P and 0B. PM2_SupportingPM3PVS1_Strong
This summary comes from the ClinGen Evidence Repository: The NM_000203.5:c.494-1G>A variant in IDUA is a canonical splice acceptor variant. This variant is predicted to cause either an in-frame deletion of exon 5 including Glu182 (PVS1), or an activation of a cryptic splice site, leading to a frameshift and premature truncation (p.Arg166ThrfsTer27) (PVS1). The available experimental data do not definitively confirm either of these outcomes, and hence the decision has been made by the ClinGen IDUA VCEP to downgrade the strength of this criterion to PVS1_Strong.The highest population minor allele frequency in gnomAD v4.1.0. is 8.477e-7 (1/1179702 alleles) in the European (non-Finnish) population, which is lower than the ClinGen Lysosomal Diseases VCEP’s threshold for PM2_Supporting (<0.00025), meeting this criterion (PM2_Supporting).This variant has been reported primarily in Turkish patients, with at least five instances in the literature: four times in a homozygous genotype (PM3), and once as part of a compound heterozygous genotype with a variant (c.826G>A) that could be considered likely pathogenic (PMID:21394825). Segregation studies for these patients were not available in this paper. There is a report of the variant in ClinVar (Variation ID: 557942). In summary, this variant meets the criteria to be classified as likely pathogenic for MPS I based on the IDUA-specific ACMG/AMP criteria applied, as specified by the ClinGen Lysosomal Diseases Variant Curation Expert Panel (Specifications Version 1.0.0): PVS1_Strong, PM2_Supporting, PM3.(Classification approved by the ClinGen Lysosomal Diseases Variant Curation Expert Panel on December 5, 2024) LINK:https://erepo.genome.network/evrepo/ui/classification/CA355961634/MONDO:0001586/091
Frequency
Consequence
NM_000203.5 splice_acceptor, intron
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_pathogenic. Variant got 7 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD3 exomes AF: 0.00000399 AC: 1AN: 250814Hom.: 0 AF XY: 0.00000736 AC XY: 1AN XY: 135798
GnomAD4 exome AF: 6.85e-7 AC: 1AN: 1460524Hom.: 0 Cov.: 32 AF XY: 0.00000138 AC XY: 1AN XY: 726606
GnomAD4 genome Cov.: 33
ClinVar
Submissions by phenotype
Mucopolysaccharidosis type 1 Pathogenic:2
Variant summary: IDUA c.494-1G>A is located in a canonical splice-site and is predicted to affect mRNA splicing resulting in a significantly altered protein due to either exon skipping, shortening, or inclusion of intronic material. Variants that disrupt the consensus splice site are a relatively common cause of aberrant splicing and loss of IDUA function. Several computational tools predict a significant impact on normal splicing: Four predict the variant weakens a canonical 5' donor site. The variant allele was found at a frequency of 4e-06 in 250814 control chromosomes. c.494-1G>A has been reported in the literature in multiple individuals affected with Mucopolysaccharidosis Type 1/Hurler syndrome (example: Atceken_2016). These data indicate that the variant is very likely to be associated with disease. The following publication has been ascertained in the context of this evaluation (PMID: 27511503). ClinVar contains an entry for this variant (Variation ID: 557942). Based on the evidence outlined above, the variant was classified as pathogenic. -
The NM_000203.5:c.494-1G>A variant in IDUA is a canonical splice acceptor variant. This variant is predicted to cause either an in-frame deletion of exon 5 including Glu182 (PVS1), or an activation of a cryptic splice site, leading to a frameshift and premature truncation (p.Arg166ThrfsTer27) (PVS1). The available experimental data do not definitively confirm either of these outcomes, and hence the decision has been made by the ClinGen IDUA VCEP to downgrade the strength of this criterion to PVS1_Strong. The highest population minor allele frequency in gnomAD v4.1.0. is 8.477e-7 (1/1179702 alleles) in the European (non-Finnish) population, which is lower than the ClinGen Lysosomal Diseases VCEP’s threshold for PM2_Supporting (<0.00025), meeting this criterion (PM2_Supporting). This variant has been reported primarily in Turkish patients, with at least five instances in the literature: four times in a homozygous genotype (PM3), and once as part of a compound heterozygous genotype with a variant (c.826G>A) that could be considered likely pathogenic (PMID: 21394825). Segregation studies for these patients were not available in this paper. There is a report of the variant in ClinVar (Variation ID: 557942). In summary, this variant meets the criteria to be classified as likely pathogenic for MPS I based on the IDUA-specific ACMG/AMP criteria applied, as specified by the ClinGen Lysosomal Diseases Variant Curation Expert Panel (Specifications Version 1.0.0): PVS1_Strong, PM2_Supporting, PM3. (Classification approved by the ClinGen Lysosomal Diseases Variant Curation Expert Panel on December 5, 2024) -
Hurler syndrome Pathogenic:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at